Scinai Immunotherapeutics Eyes Pincell srl Acquisition
Ticker: SCNI · Form: 6-K · Filed: Sep 22, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition-target, biotech, pipeline-expansion
TL;DR
Scinai looking to buy Pincell srl and its monoclonal antibody PC111.
AI Summary
Scinai Immunotherapeutics Ltd. announced on September 22, 2025, that it is anticipating the signing of an option agreement to acquire Pincell srl, an Italian biotech company. Pincell srl owns PC111, a monoclonal antibody currently in development for the treatment of certain conditions.
Why It Matters
This potential acquisition could expand Scinai's pipeline with a new monoclonal antibody, potentially impacting its future therapeutic offerings and market position.
Risk Assessment
Risk Level: medium — The filing indicates an anticipated option agreement, meaning the acquisition is not yet finalized and is subject to further negotiation and conditions.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- Pincell srl (company) — Target company for acquisition
- PC111 (drug_candidate) — Monoclonal antibody being developed by Pincell srl
FAQ
What is the specific indication for which PC111 is being developed?
The filing states PC111 is in development for 'the treatment of certain conditions' but does not specify the exact indication.
When is the option agreement for the acquisition of Pincell srl expected to be signed?
The filing indicates the agreement is anticipated to be signed, but does not provide a specific date.
What is the name of the Italian biotech company Scinai Immunotherapeutics is looking to acquire?
Scinai Immunotherapeutics is looking to acquire Pincell srl.
What type of therapeutic agent is PC111?
PC111 is a monoclonal antibody.
Has Scinai Immunotherapeutics Ltd. previously been known by another name?
Yes, Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd., with a name change date of June 24, 2014.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 14.9 · Accepted 2025-09-22 08:27:04
Filing Documents
- ea0258206-6k_scinai.htm (6-K) — 13KB
- 0001213900-25-089839.txt ( ) — 14KB
Forward-Looking Statements
Forward-Looking Statements This Report contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements are based upon the Company’s present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For this reason, among others, you should not place undue reliance upon the Company’s forward-looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Report. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: September 22, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2